16: One of the most-anticipated FDA decisions of the first half of 2024 came early as the regulator approved Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy (exagamglogene autotemcel) as a one-time treatment for transfusion-dependent beta-thalassemia (TDT)
In this study, scientists compared two similar drugs, cagrilintide and KBP-336, to see if there were any important differences in how they work
Conclusion: The Future of Energy Homeostasis The transition from treating metabolic symptoms to addressing the underlying bioenergetic causes is the current frontier of science
The newly discovered compounds significantly reduced LPS-induced production of IL-6, IL-1, and TNF- in microglial cells
Treatment and Monitoring We guide you through administration or provide in-home care, ensuring proper dosage, timing, and follow-up
Studies consistently show enhanced blood vessel formation in BPC-157 treated tissues